Activery The amorphization specialist
Activery believes that amorphous drugs provide new and innovative routes to final dosage forms with differentiated pharmacokinetics
| Impax said the U.S. Food & Drug Administration accepted for filing its abbreviated new drug application (ANDA) containing a paragraph IV certification for a generic version of Oracea |
 |
 |
 |
|
Impax's Parkinson drug shows promise in mid-stage trial Sept 21 (Reuters) - Drugmaker Impax Laboratories Inc's (IPXL.O: Cotización) unit said its experimental drug to treat late-stage Parkinson's disease showed positive results in a mid-stage trial. Impax said its drug IPX066 reduced Parkinson's patients' "off" time, a key objective in the management of the disease, during waking hours by 2 hours compared to current standard of care Bristol-Meyers Squibb's (BMY.N: Cotización) Sinemet. Separately, the company said it initiated a challenge of the patents listed by Galderma Laboratories on Oracea -- a drug used to treat inflammatory lesions. Galderma is a joint-venture between Swiss food maker Nestle (NESN.VX: Cotización) and French cosmetics company L'Oreal (OREP.PA: Cotización). Impax said the U.S. Food & Drug Administration accepted for filing its abbreviated new drug application (ANDA) containing a paragraph IV certification for a generic version of Oracea. "Once the ANDA is approved by FDA, Global Pharmaceuticals, Impax's generic division, will commercialize the product," Impax said. Last week, the Research Foundation of State University of New York, New York University and Galderma Laboratories filed suit for patent infringement against Impax. |
Pharma Notes
- New study on Inhaled Drug Delivery Market
- Particles that deliver larger and more effective doses of drugs to cancers
- The global protein therapeutics market will be worth $77bn by 2011 with biogenerics playing an increasingly important rol
- A federal jury in Texas Monday upheld the patent on Johnson & Johnson's arthritis treatment Remicade and ordered Abbott Laboratories to pay its rival $1.67 billion for infringing on the patent
- Transdermal delivery represents an attractive alternative to oral delivery of drugs and is poised to provide an alternative to hypodermic injection tool
Differentiated Generics
- Teva may lose patent challenge
- Labopharm receives notice of ANDA submission with paragraph IV certification for generic of Ryzolt
- Depomed (DEPO) Receives Paragraph IV Notice from Lupin Limited Over Patent Filing for Generic Glumetza Tablets
- The rate and number of successful Paragraph IV challenges is reducing the average effective patent life for innovator drugs
- Teva Sues Mylan Over Multiple Sclerosis Drug COPAXONE
Nanoparticles world
- Nanoparticle created to attack cardiovascular plaque
- Nanoparticle lung threat blocked
- Newly-developed nanoparticle to build therapies for treating individuals with cardiovascular disease.
- Nanoparticle Processing in the Solid State Dramatically Increases the Cell Membrane Permeation of a Cholesterol-Lowering Drug, Probucol
- Erectile dysfunction could be treated by a nanoparticle formulation applied directly to the penis